Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

We have previously shown that the addition of the raltegravir/elvitegavir (RAL/EVG) primary resistance mutation N155H to the R263K dolutegravir (DTG) resistance mutation partially compensated for the fitness cost imposed by R263K while also slightly increasing DTG resistance in vitro (K. Anstett, T....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Virol
Auteurs principaux: Anstett, Kaitlin, Fusco, Robert, Cutillas, Vincent, Mesplède, Thibault, Wainberg, Mark A.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2015
Sujets:
Vaccines and Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580168/
https://ncbi.nlm.nih.gov/pubmed/26246578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01725-15
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires